JB
VIR icon

Julian Baker’s Vir Biotechnology VIR Stock Holding History

Julian Baker’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-542,539
Closed -$3.27M – 92
2025
Q4 		$3.27M Hold
542,539
– – 0.02% 78
2025
Q3 		$3.1M Hold
542,539
– – 0.02% 78
2025
Q2 		$2.73M Hold
542,539
– – 0.03% 73
2025
Q1 		$3.52M Sell
542,539
-542,000
-50% -$4.82M 0.04% 66
2024
Q4 		$7.96M Buy
+1,084,539
New +$8.55M 0.09% 58

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Julian Baker's VIR Position: Q1 2026 in Review

Julian Baker sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 542,539 shares — an estimated $3.27M sold.

Julian Baker first reported a position in VIR in Q4 2024 and held it in 5 quarters. The position peaked at $7.96M in Q4 2024. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Julian Baker reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Julian Baker sold 542,539 Vir Biotechnology shares in Q1 2026, an estimated $3.27M.
  • Julian Baker first reported a position in Vir Biotechnology in Q4 2024 and held it in 5 quarters.
  • Julian Baker's Vir Biotechnology position peaked at $7.96M in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.